has approved Novo Nordisk's Ozempic to lower the risk of kidney failure and disease progression. According to a statement made by the Danish pharmaceutical company, approval has also been obtained ...

Ozempic generated $13.9bn in global sales for Novo Nordisk in 2023. The drug is forecast to reach $23.9bn in sales by 2030, according to GlobalData’s Pharma Intelligence Center. GlobalData is the ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

The Danish drug giant Novo Nordisk, known for its antidiabetes and weight loss ... the self-regulatory body that administers the code of practice of the Association of the British Pharmaceutical ...

This issue is preventing our website from loading properly. Please review the following troubleshooting tips or contact us at [email protected]. By submitting your ...

Moderna and Novo Nordisk are once again in the bad books ... earning it a suspension from the Association of the British Pharmaceutical Industry (ABPI) and a series of admonishments for ...

The latest announcement led to shares of the company increasing by 7.13%. Credit: Novo Nordisk. Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating ...

Novo Nordisk (NVO) has reportedly been criticized ... a self-regulatory body which administers the Association of the British Pharmaceutical Industry's Code of Practice, said in a report issued ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

On Tuesday, BofA Securities expressed continued confidence in Novo Nordisk (NOVOB ... amidst various industry discussions surrounding the pharmaceutical giant's future performance and competitive ...